- Home
- CRNT vs SGMT Comparison
CRNT vs SGMT Comparison
Compare CRNT & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRNT
- SGMT
- Stock Information
- Founded
- CRNT 1996
- SGMT 2006
- Country
- CRNT Israel
- SGMT United States
- Employees
- CRNT N/A
- SGMT N/A
- Industry
- CRNT Radio And Television Broadcasting And Communications Equipment
- SGMT
- Sector
- CRNT Technology
- SGMT
- Exchange
- CRNT Nasdaq
- SGMT Nasdaq
- Market Cap
- CRNT 218.8M
- SGMT 230.3M
- IPO Year
- CRNT 2000
- SGMT 2023
- Fundamental
- Price
- CRNT $1.99
- SGMT $6.85
- Analyst Decision
- CRNT Strong Buy
- SGMT Strong Buy
- Analyst Count
- CRNT 4
- SGMT 7
- Target Price
- CRNT $5.50
- SGMT $26.57
- AVG Volume (30 Days)
- CRNT 543.5K
- SGMT 563.9K
- Earning Date
- CRNT 08-06-2025
- SGMT 08-13-2025
- Dividend Yield
- CRNT N/A
- SGMT N/A
- EPS Growth
- CRNT 34.68
- SGMT N/A
- EPS
- CRNT 0.15
- SGMT N/A
- Revenue
- CRNT $380,518,000.00
- SGMT N/A
- Revenue This Year
- CRNT N/A
- SGMT N/A
- Revenue Next Year
- CRNT $7.19
- SGMT N/A
- P/E Ratio
- CRNT $13.39
- SGMT N/A
- Revenue Growth
- CRNT 5.06
- SGMT N/A
- 52 Week Low
- CRNT $1.82
- SGMT $1.73
- 52 Week High
- CRNT $5.73
- SGMT $11.41
- Technical
- Relative Strength Index (RSI)
- CRNT 45.17
- SGMT 37.89
- Support Level
- CRNT $1.97
- SGMT $6.77
- Resistance Level
- CRNT $2.07
- SGMT $7.35
- Average True Range (ATR)
- CRNT 0.06
- SGMT 0.42
- MACD
- CRNT 0.01
- SGMT -0.01
- Stochastic Oscillator
- CRNT 42.86
- SGMT 7.34
About CRNT Ceragon Networks Ltd.
Ceragon Networks Ltd is a wireless transport company in terms of unit shipments and wide distribution of its business, providing high-capacity wireless connectivity solutions to markets across various industries, mainly wireless (mobile) networks service providers. Geographically the company generates the key revenue from India. The company also has presence in North America, Europe, Africa, Asia-Pacific and Middle East, and Latin America. The company's products include IP-50 Platform, IP-20 Platform, Pointlink.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.